Department of Surgery, Kosin University College of Medicine, Busan, Korea.
Cancer Res Treat. 2008 Mar;40(1):33-5. doi: 10.4143/crt.2008.40.1.33. Epub 2008 Mar 31.
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in which the patients suffered from intestinal perforation after chemotherapy with bevacizumab. For the first case, a 47 year-old man had rectal cancer with concurrent liver and lung metastasis. He underwent chemotherapy with 5-fluorouracil, irinotecan and bevacizumab. Fever and abdominal pain developed seven days later, and rectal perforation was identified upon exploration 13 days later. For the second case, a 48 year-old woman had sigmoid colon cancer with peritoneal and ovary metastases. After seven days of chemotherapy with 5-fluorouracil, oxaliplatin and bevacizumab, exploratory surgery revealed a perforation at the ileum.
贝伐珠单抗是一种针对血管内皮生长因子（VEGF）的单克隆抗体，已被证明是一种有前途的治疗转移性结直肠癌的临床药物，特别是与化疗联合使用时。肠穿孔是贝伐珠单抗使用相关的已知风险，但病因不明。在这里，我们报告了两例转移性结直肠癌患者，他们在接受贝伐珠单抗化疗后发生了肠穿孔。对于第一个病例，一名 47 岁男性患有直肠癌，同时伴有肝和肺转移。他接受了 5-氟尿嘧啶、伊立替康和贝伐珠单抗化疗。化疗后 7 天出现发热和腹痛，13 天后探查发现直肠穿孔。对于第二个病例，一名 48 岁女性患有乙状结肠癌，伴有腹膜和卵巢转移。接受 5-氟尿嘧啶、奥沙利铂和贝伐珠单抗化疗 7 天后，剖腹手术显示回肠穿孔。
